Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
64 hedge funds and large institutions have $52.5M invested in Sorrento Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 26 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 68 → 64 (-4)
25% less call options, than puts
Call options by funds: $33K | Put options by funds: $44K
26% less capital invested
Capital invested by funds: $71.1M → $52.5M (-$18.6M)
46% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.86M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$545K |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$143K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$138K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$97.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$1.32M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.09M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$792K |
| 4 |
MOACM
Mutual of America Capital Management
New York
|
-$741K |
| 5 |
Millennium Management
New York
|
-$590K |
SRNE Hedge Fund Activity: Q1 2017 in Review
64 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2017, worth a combined $52.5M — down 26% from $71.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SRNE positions and 6 closed out — a net gain of 1 holder — while 14 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $7.86M. The largest seller was Avoro Capital Advisors, cutting an estimated $1.32M.
- 64 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2017, down from 68 in Q4 2016.
- Funds reported $52.5M of Sorrento Therapeutics, Inc. stock for Q1 2017, down 26% quarter-over-quarter.
- 7 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2017 and 6 closed out, a net change of +1 holder.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $7.86M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2017 was Avoro Capital Advisors, an estimated $1.32M sold.
Based on aggregated 13F filings for Q1 2017.